Insider Selling: Omada Health (NASDAQ:OMDA) CFO Sells 1,607 Shares

Key Points

• Omada Health CFO Steven Cook sold 1,607 shares at an average price of $25.01, generating approximately $40,191 and reducing his direct stake by 0.85% to 187,209 shares.
• OMDA shares fell 0.7% to $23.84, while the company trades at a very high P/E ratio of about 477. The stock remains near its 12-month high despite valuation risks.
• Omada’s latest quarterly results exceeded expectations, with EPS of $0.08 versus an expected loss of $0.02 and revenue of $87.83 million versus estimates of $80.93 million; analysts maintain a broadly favorable “Moderate Buy” consensus.

Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) CFO Steven Cook sold 1,607 shares of Omada Health stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $25.01, for a total transaction of $40,191.07. Following the completion of the transaction, the chief financial officer directly owned 187,209 shares in the company, valued at $4,682,097.09. This represents a 0.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Omada Health Stock Down 0.7%

NASDAQ:OMDA traded down $0.17 during trading hours on Wednesday, reaching $23.84. 1,552,408 shares of the company's stock were exchanged, compared to its average volume of 1,274,695. The company has a market capitalization of $1.46 billion, a P/E ratio of 476.80 and a beta of 1.73. The business's 50-day simple moving average is $20.61 and its two-hundred day simple moving average is $16.32. Omada Health, Inc. has a 12 month low of $10.28 and a 12 month high of $26.92.

Omada Health (NASDAQ:OMDA - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.10. Omada Health had a return on equity of 2.67% and a net margin of 1.39%.The company had revenue of $87.83 million for the quarter, compared to analyst estimates of $80.93 million. As a group, sell-side analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in OMDA. Quantbot Technologies LP acquired a new stake in shares of Omada Health during the 2nd quarter valued at $1,695,000. Ieq Capital LLC purchased a new stake in shares of Omada Health during the second quarter worth $1,728,000. AlpInvest Partners B.V. acquired a new stake in Omada Health during the second quarter valued at $1,182,000. BlackRock Inc. purchased a new position in Omada Health in the second quarter valued at about $48,775,000. Finally, Deutsche Bank AG acquired a new position in Omada Health in the 2nd quarter worth about $777,000.

Trending Headlines about Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Omada’s second-quarter results provided further evidence that revenue growth is translating into profitability. The company reported earnings of $0.08 per share versus a consensus loss of $0.02 and revenue of approximately $87.8 million, well above the $80.9 million analyst estimate. The results support the bullish case for Omada’s digital chronic-care platform and improving financial execution. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
• Positive Sentiment: Robert W. Baird raised its price target on OMDA from $15 to $25, reflecting improved expectations following the earnings performance. However, the firm maintained a neutral rating, indicating that much of the near-term upside may already be reflected in the stock price. Benzinga analyst update
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with a reported consensus rating of “Moderate Buy” and an average price target of $25.67. Recent targets range from $24 to $35, but the wide range highlights uncertainty around valuation and future growth.
• Neutral Sentiment: Reported short interest was zero shares, offering no meaningful indication of short-selling pressure or potential short-covering demand.
• Negative Sentiment: CEO Sean Duffy disclosed sales of 8,628 shares at an average price of $21.85 and 12,942 shares at $24.81. The transactions reduced his direct ownership by roughly 5% across the reported sales and may weigh on sentiment, although he still owns more than 411,000 shares.
• Negative Sentiment: At roughly $24 per share, OMDA trades at a very high price-to-earnings ratio near 480, leaving the stock sensitive to disappointment in growth, margins or future earnings. Its recent performance has already placed it well above its 50-day and 200-day moving averages.

Analyst Upgrades and Downgrades

A number of research firms have commented on OMDA. Citigroup reaffirmed an "outperform" rating on shares of Omada Health in a research note on Monday, July 20th. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Omada Health in a research note on Friday, May 8th. Weiss Ratings downgraded shares of Omada Health from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Monday, July 13th. Citizens Jmp raised their target price on Omada Health from $21.00 to $27.00 and gave the stock a "market outperform" rating in a research report on Monday, July 20th. Finally, BMO Capital Markets reiterated an "outperform" rating and set a $24.00 price target on shares of Omada Health in a report on Friday, August 7th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $25.75.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source